)
Overview
<ul>
<li>Rare disease company reported Q2 fiscal 2026 net loss of $22.8 mln, up from last year</li>
<li>R&amp;D expenses rose to $14.3 mln due to increased clinical trial activities</li>
</ul>
Outlook
<ul>
<li>Rezolute to meet FDA by end of Q1 under Breakthrough Therapy Designation</li>
<li>Topline results for tumor HI study expected in H2 2026</li>
</ul>
Result Drivers
<ul>
<li>INCREASED R&amp;D EXPENSES - R&amp;D expenses rose due to increased clinical trial activities and employee-related costs, including severance benefits</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
<h3>Q2 EPS -$0.22</h3>
Q2 Net -$22.77
Income mln
<h3>Q2 -$24.22</h3>
Income mln
From
Operatio
ns
<h3>Q2 $24.22</h3>
Operatin mln
g
Expenses
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 6 “strong buy” or “buy”, 4 “hold” and no “sell” or “strong sell”</li>
<li>Wall Street’s median 12-month price target for Rezolute Inc is $5.00, about 48.4% above its February 11 closing price of $3.37</li>
</ul>
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Rare disease firm Rezolute's Q2 net loss widens